Skip to main content

Drug Interactions between Bioclate and Palynziq

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

antihemophilic factor pegvaliase

Applies to: Bioclate (antihemophilic factor) and Palynziq (pegvaliase)

MONITOR: Coadministration of pegvaliase with other PEGylated products may increase the risk of hypersensitivity reactions, including anaphylaxis. In a single-dose study of pegvaliase in adults with phenylketonuria, two patients experienced hypersensitivity reactions during concomitant injections of medroxyprogesterone acetate suspension, a formulation containing PEG 3350. The first patient experienced a hypersensitivity reaction on day 15 after a single 0.67 mg dose of pegvaliase within 15 minutes following medroxyprogesterone acetate injection, and subsequently experienced anaphylaxis on day 89 within 30 minutes after the next dose of medroxyprogesterone acetate injection. The second patient experienced a hypersensitivity reaction on day 40 after a single 0.08 mg dose of pegvaliase within 10 minutes following medroxyprogesterone acetate injection. Both patients had high anti-PEG IgG antibody titers at or around the time of the hypersensitivity reactions. In clinical trials, the majority of patients developed anti-PEG IgM and IgG antibodies after treatment with pegvaliase. The clinical effects of concomitant treatment with different PEGylated products is unknown.

MANAGEMENT: Close monitoring for anaphylaxis and other hypersensitivity reactions is recommended during concomitant use of pegvaliase with other PEGylated products or products that contain polyethylene glycol (e.g., certolizumab pegol; doxorubicin liposomal; eflapegrastim; epoetin beta-methoxy polyethylene glycol; irinotecan liposomal; medroxyprogesterone acetate suspension; naloxegol; pegademase bovine; pegaptanib; pegaspargase; pegfilgrastim; peginesatide; peginterferons; pegloticase; pegvisomant; certain formulations of recombinant antihemophilic factor and coagulation factor IX).

References

  1. (2018) "Product Information. Palynziq (pegvaliase)." BioMarin Pharmaceutical Inc

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer